Back to search

National and Kapodistrian University of Athens

Η επίδραση των νεότερων αντιδιαβητικών αγωγών στη μεταβολή βιοδεικτών και η συσχέτιση τους με την αγγειακή και την καρδιακή λειτουργία σε ασθενείς με σακχαρώδη διαβήτη τύπου 2

Abstract

dc:description

Disturbance of balance between oxidative stress burden and antioxidant defenses is involved in the clinical course of atherosclerosis among type 2 diabetic patients. Two novel antidiabetic classes of agents, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and GLP1-RA glucagon-like peptide-1 receptor agonists (GLP1-RA), are advocated for the treatment of diabetic patients who pose high cardiovascular risk. We have previously demonstrated that treatment with the combination GLP-1RA+SGLT-2i provides greater improvement of arterial stiffness, thickness of endothelial glycocalyx, myocardial work, ventriculoarterial coupling compared with the separate administration of each agent or insulin and this effect appears to be independent of glycemic regulation. The aim of the present study was to address the effects of insulin, GLP1-RA, SGLT-2i, and their combination on levels of oxidant and antioxidant biomarkers. For this reason, we finally recruited a total of 160 type 2 diabetic patients, who received insulin (n=40), liraglutide (n=40), empagliflozin (n=40), or their combination (liraglutide + empagliflozin) (n=40). We recorded at baseline, at 4 months and at 12 months after recruitment: (a) Thiobarbituric Acid Reactive Substances (TBARS), which is a biomarker of oxidative stress burden (b) Malondialdehyde (MDA), which is a biomarker of oxidative stress burden (c) Reducing Power (RP), which is an antioxidant biomarker, (d) 2,2¢-azino-bis-(3-ethylbenzthiazoline-6-sulphonic acid) radical (ABTS), which is an antioxidant biomarker and (e) Total Antioxidant Capacity (TAC), which is an antioxidant biomarker. All participants achieved significant reduction of hemoglobin A1C (HbA1C) after treatment (p<0,05) and we did not observe differences between treatment arms (p>0,05). Dual treatment provided significant decline of both oxidant biomarkers TBARS, MDA and also a significant rise of the antioxidant biomarker ABTS at 4 months compared with the other study groups (p<0,05 for all comparisons). At twelve months all participants improved TBARS, MDA and ABTS (p<0,05). At 12 months, GLP1-RA and GLP-1RA+SGLT2i provided a greater reduction of TBARS (-8,76% and -9,83% correspondingly) compared with the other 2 study groups, insulin or SGLT2i (-0,5% and 3,22% respectively), (p<0,05). GLP1-RA and GLP-1RA+SGLT-2i showed a greater improvement of MDA (-30,15% and -31,44% respectively) in contrary with insulin and SGLT2i groups (4,72% and -3,74% correspondingly), (p<0,05). SGLT2i and GLP-1RA+SGLT2i showed remarkable increase of ABTS levels (12,87% and 14,13% respectively) compared with insulin and GLP1-RA (2,44% and -3,44% respectively), (p<0,05). Furthermore, only dual treatment resulted in significant improvement of TAC compared with the other study groups at 12 months of treatment (p<0,05). Consequently, 12-month treatment with GLP1-RA and SGLT2i resulted in great reduction of biomarkers responsible for oxidative modifications and increase of antioxidant defenses respectively. These robust effects are independent of glycemic control. Interestingly, the combination group was shown to be superior and additive to each separate agent and also the beneficial effects were apparent earlier.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Thymis, Ioannis
  • Θυμής, Ιωάννης

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/52790

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Thymis, Ioannis; Θυμής, Ιωάννης. Η επίδραση των νεότερων αντιδιαβητικών αγωγών στη μεταβολή βιοδεικτών και η συσχέτιση τους με την αγγειακή και την καρδιακή λειτουργία σε ασθενείς με σακχαρώδη διαβήτη τύπου 2. National and Kapodistrian University of Athens, 2022. http://hdl.handle.net/10442/hedi/52790